Background: Electrical burns, although less prevalent, are devastating injuries and are associated with high morbidity and mortality. This study assessed the socio-demographic characteristics, complications, surgical interventions and outcomes among electrical burn victims.
Methods: From 2013 to 2018, patients who suffered from electric burns and were admitted to Burns Unit, Department of Plastic Surgery, Kasturba Hospital, Manipal, India were enrolled.
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance during chemotherapy. Nanoparticles with sustainable release profile will help in targeted delivery of anticancer drugs while minimizing deleterious side effects and drug resistance.
View Article and Find Full Text PDF